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Abstract
Background: Disclosure of authors’ financial interests has been proposed as a strategy for protecting the integrity of the
biomedical literature. We examined whether authors’ financial interests were disclosed consistently in articles on coronary
stents published in 2006.
Methodology/Principal Findings: We searched PubMed for English-language articles published in 2006 that provided
evidence or guidance regarding the use of coronary artery stents. We recorded article characteristics, including information
about authors’ financial disclosures. The main outcome measures were the prevalence, nature, and consistency of financial
disclosures. There were 746 articles, 2985 authors, and 135 journals in the database. Eighty-three percent of the articles did
not contain disclosure statements for any author (including declarations of no interests). Only 6% of authors had an article
with a disclosure statement. In comparisons between articles by the same author, the types of disagreement were as
follows: no disclosure statements vs declarations of no interests (64%); specific disclosures vs no disclosure statements
(34%); and specific disclosures vs declarations of no interests (2%). Among the 75 authors who disclosed at least 1
relationship with an organization, there were 2 cases (3%) in which the organization was disclosed in every article the author
wrote.
Conclusions/Significance: In the rare instances when financial interests were disclosed, they were not disclosed
consistently, suggesting that there are problems with transparency in an area of the literature that has important
implications for patient care. Our findings suggest that the inconsistencies we observed are due to both the policies of
journals and the behavior of some authors.
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Introduction
The influence of commercial interests on medical science is an
area of ongoing concern. Recent work has examined the extent of
this influence [1–5] and explored best practices for managing
conflicts of interest [6–9]. A particular area of concern is the
influence of conflicts of interest on the biomedical literature.
Disclosure of authors’ financial interests in journal articles has
been proposed as one strategy for protecting the integrity of
research and maintaining public trust [10–12]. The International
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2128Committee of Medical Journal Editors (ICMJE) and the World
Association of Medical Editors, among others, encourage
disclosure of authors’ financial interests [10,13–15].
Despite repeated calls for financial disclosures and the growing
number of journals with conflict-of-interest policies [12,16–18],
the effectiveness of current approaches to disclosure remains
unclear [16,19–23]. How one defines effectiveness may depend on
the parties involved, be they authors, editors, reviewers, or readers.
For readers of the medical literature, it might be reasonable to
expect that authors’ financial interests are disclosed in similar ways
in articles on the same topic published around the same time. A
system of disclosure that was not consistent in this way might
create confusion or mistrust among readers and the public. In this
study, we examined all articles on coronary stents published in
2006 to determine whether authors’ financial interests were
reported consistently.
A coronary stent is a flexible metal tube inserted into a coronary
artery to hold the artery open. Stents are widely used in patients
with coronary disease to restore or maintain blood flow to the
heart muscle, which is critically dependent on high rates of blood
flow. Coronary stents have come under intense scrutiny, including
disagreements about their effectiveness [24], controversy in the
United States regarding an early decision to adjust Medicare
payments for drug-eluting stents [25], and concerns about the
financial interests of US Food and Drug Administration advisory
panel members [26]. Messages that appear in the medical
literature regarding the effectiveness of stents affect a multibil-
lion-dollar industry that includes companies that produce stents
and products that support stents, as well as companies that
produce alternatives to stents. The integrity of this literature is
important for disseminating accurate information about the risks
and benefits of stents. The controversy, financial stakes, and
impact on patients’ welfare make this an appropriate literature to
study regarding the disclosure of potential conflicts of interest.
Methods
Data Sources
In March 2007, we searched PubMed for English-language
articles published in 2006 and indexed with the Medical Subject
Heading (MeSH) terms ‘‘stents,’’ ‘‘heart diseases,’’ and ‘‘humans.’’
We limited the search to articles published in 2006 because this was
the most recent year for which data were available; and we limited
the search to a single year on the assumption that financial interests
change over time and would be more or less stable within a year.
Twoofusindependentlyreviewedthearticlesandselectedthosethat
provided evidence or guidance regarding the use of coronary artery
stents. The reviewers reconciled their determinations by consensus,
and a third reviewer resolved disagreements and uncertainties. We
excluded 2 articles for which no authors were listed.
Because many author names were associated with multiple
articles, we sought to ensure that each author in the database was
represented by a single term. First, we combined authors who were
indexed in Medline under different names for different articles.
For example, if we determined that author ‘‘Smith J’’ in one article
and author ‘‘Smith JA’’ in another article were the same person,
we marked both instances as ‘‘Smith JA’’ in the database. Next, we
separated different authors who were indexed in Medline under
the same name. For example, if we determined that author ‘‘Jones
A’’ in one article was not the same person as author ‘‘Jones A’’ in
another article, we marked one author as ‘‘Jones AA’’ and the
other as ‘‘Jones AB.’’
We constructed a Microsoft Access database for the analysis that
contained the complete Medline citation for each article, including
author names, publication types, and MeSH terms. We recorded
whether each article contained a statement regarding financial or
material support for the work; sources and types of support; and
whether the article described authors’ contributions to the work. If
the article described authors’ contributions, we recorded each
author’s contributions. If the article contained a statement regarding
authors’ financial interests, we recorded the types of interests and the
organizationswithwhicheachauthorhadthespecifiedrelationships.
If the article directed readers to supplemental disclosure information
located elsewhere (eg, the journal’s Web site), we included the
supplemental information in our coding.
We consulted ISI Journal Citation Reports to determine journal
impact factors as an indicator of the influence of each journal [27].
We used the 2005 impact factor for each journal (the most recent
available at the time of the study), defined as the average number
of times that articles published in the journal in the previous 2
years were cited in 2005. We also determined whether
representatives of each journal requested listing as endorsers of
the ICMJE guidelines, as reported by the ICMJE [28].
Statistical Analysis
We categorized articles as ‘‘research’’ if they reported original
research or a case study. We categorized the remaining articles as
‘‘other,’’ which included mostly commentaries and letters. We
report simple frequencies and percentages for whether sources of
funding were disclosed for research articles, excluding case reports.
(Because case reports are drawn from clinical practice, we
reasoned that no funding source statement would be expected.)
We used x
2 tests to examine relationships between reporting a
source of funding and endorsement of the ICMJE guidelines. We
used a Wilcoxon rank sum test to examine the relationship
between reporting a source of funding and the impact factor of the
journal in which the article was published.
If an article contained a statement describing an author’s
financial interests (including a declaration of no interests), we
considered a disclosure statement to be present. We coded each
article as having disclosure statements for all, some, or none of the
authors. We used x
2 tests to examine the relationships between the
presence of disclosure statements for authors (all, some, or none)
and type of article and endorsement of the ICMJE guidelines. We
used a Wilcoxon rank sum test to examine the relationship
between the presence of a disclosure statement for authors (all vs
some or none) and the impact factor of the journal in which the
article was published.
Prevalence and Nature of Disclosures
We examined the prevalence and nature of authors’ financial
disclosures by analyzing every instance in which a disclosure might
have appeared (hereafter termed author instances). The number of
author instances is the sum of the number of authors from all
articles in the database. For example, if someone authored 6
articles, that person contributed 6 author instances to the data set.
Across author instances, we examined the presence or absence of a
disclosure statement. We used x
2 tests to compare the frequencies
of disclosure statements between research articles and other
articles. We conducted the same analysis after removing case
reports from the research category.
Consistency of Disclosures
For authors with more than 1 article, we analyzed the consistency
with which disclosure statements appeared across multiple articles.
We conducted this analysis in two ways. First, we determined
whether there was consistency within author in the presence or
absence of any type of financial disclosure statement. Second, for
Consistency of Disclosures
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2128authors who disclosed at least 1 relationship with a commercial
organization, we evaluated the consistency within author of the
contentofthedisclosures.Wedescribe each oftheseanalyses inturn.
Consistency in the Presence or Absence of Disclosure
Statements. We designed this part of the analysis to identify
authors whose articles always, sometimes, or never agreed in terms
of the presence or absence of a disclosure statement. Thus, for
each author, we estimated the proportion of all unique pairwise
article comparisons that agreed in terms of the presence of a
financial disclosure, a declaration of no interests, or an absence of
any disclosure statement. (Note that for these analyses, 2 articles by
the same author in which 2 different organizations were disclosed
would be counted as agreement. A later analysis addressed
consistency in the organizations disclosed.) For example, consider
an author of 4 articles with the following disclosures: article 1
(relationship with a company), article 2 (relationship with a
company), article 3 (declaration of no interests), article 4 (no
disclosure statement). In this case, there are 6 unique pairwise
comparisons, and 1 pair is in agreement (articles 1 and 2).
Therefore, the proportion agreement for the author is 1/6 (0.17).
We report the frequencies of authors with proportion agreement
equal to 0 (no articles agree), 1 (all articles agree), and between 0
and 1 (some articles agree).
We also examined the frequency of types of agreement (present–
present, none declared–none declared, absent–absent) and disagree-
ment (present–none declared, present–absent, none declared–
absent). Due to the small average number of articles per author,
we collapsed these types of agreement across all comparisons for all
authors. To examine how disagreements might be a function of
journal policies, we report whether the disagreements occurred
within the same journal and whether they occurred within the same
article type (research–research vs research–other). Because some
readers might consider listing an author’s affiliation with a company
as a disclosure (in lieu of a specific disclosure statement), we
determined the number of industry-affiliated authors contributing to
each type of agreement and disagreement.
Consistency in the Content of Disclosure Statements. To
determine the consistency of authors’ disclosure statements, we
examined authors who had multiple articles and disclosed at least 1
financial interest. For each of these authors, we first counted the
number of unique organizations with which the author disclosed a
relationship in any of the author’s articles. (In some cases, a
relationship with more than 1 organization was disclosed in a single
article.) Consider a hypothetical example in which an author has 4
articles with the following disclosures: article 1 (relationship with
company A), article 2 (relationships with company A and company
B), article 3 (no disclosure statement), and article 4 (relationship with
company A). This author has 4 articles in which 2 unique
organizations—companies A and B—appear in disclosure
statements. Next, for each of the unique organizations associated
with an author, we counted the number of organizations that were
disclosed in all of the author’s articles. In the hypothetical example,
company A is disclosed in 3 of the 4 articles and company B is
disclosed in 1 of the 4 articles. Thus, none of this author’s
organizationsaredisclosedinall4ofthearticles.Foreachauthor,we
calculated the proportion of unique organizations with which the
author disclosed a relationship that were disclosed in each of the
author’s articles, and we summarized the distribution of these
proportions across authors.
Results
We retrieved 746 articles, of which 623 were research articles
(eg, clinical trials, case reports, meta-analyses) and 123 were
commentaries, letters, and other communications that did not
present original research. There were 2985 authors and 135
journals. The number of articles per author ranged from 1 to 25.
Of the 441 research articles (excluding case reports), 316
(71.7%) did not include a statement identifying the source of
support for the study (including declarations of no support). These
statements were more likely to appear in journals that endorsed
the ICMJE guidelines (34% vs 21%; x
2=9.3; p=0.002) and in
journals with higher impact factors (median impact factor, 3.55 vs
3.06; p=0.04). A total of 125 organizations were listed as sources
of support. The top 5 sources (ie, Johnson & Johnson, Boston
Scientific, CardioVascular Research Foundation [South Korea];
Ministry of Health and Welfare [South Korea]; and Guidant)
accounted for 28% of the articles in which a source of support was
declared.
Eight of the 623 research articles (1.3%) contained statements
describing the contributions made by each author.
Financial Disclosures
Table 1 shows the percentages of articles in which a disclosure
statement was present for all, some, or none of the authors.
Overall, 116 articles (15.5%) contained a disclosure statement for
all authors, and 620 articles (83.1%) did not contain a disclosure
statement for any author. Articles in journals that endorsed the
ICMJE guidelines were more likely than other articles to have
disclosure statements for all authors (25.3% vs 7.4%). Articles in
which all authors had disclosure statements were more likely to
appear in journals with higher impact factors (median impact
factor, 11.63 vs 3.06; p,0.001).
Prevalence and Nature of Disclosures
A total of 168 authors (5.6%) had a disclosure statement in at
least 1 article. The combination of authors and articles resulted in
4664 author instances (ie, opportunities for disclosure). Of these
author instances, 220 (4.7%) had a disclosure, 577 (12.4%) had a
declaration of no interests, and 3867 (82.9%) had no disclosure
statement (Table 2). Author instances in research articles were
slightly less likely to have a disclosure statement than author
instances in other articles. Excluding case reports did not change
the percentages by more than 1 percentage point (data not shown).
Table 1. Articles with disclosure statements for all, some, or
no authors.*
Characteristic Articles (N=746) p{
Disclosure
statement
for all
authors
Disclosure
statement
for some
authors
Disclosure
statement
for no
authors
Article type 0.05
All 116 (15.5) 10 (1.3) 620 (83.1)
Research 88 (14.1) 9 (1.4) 526 (84.4)
Other 28 (22.8) 1 (0.8) 94 (76.4)
Journal endorsement of
ICMJE guidelines
,0.001
No 30 (7.4) 5 (1.2) 371 (91.4)
Yes 86 (25.3) 5 (1.5) 249 (73.3)
Abbreviation: ICMJE, International Committee of Medical Journal Editors.
*Data are expressed as n (row %) unless otherwise indicated.
{p values are from x
2 tests.
doi:10.1371/journal.pone.0002128.t001
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PLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2128The maximum number of financial interests disclosed for a
single author in a single article was 4. The disclosed relationships
referred to 78 organizations. The 5 most frequent organizations
(ie, Johnson & Johnson, Boston Scientific, Medtronic, Sanofi-
Aventis, and Bristol-Myers Squibb) accounted for 59% of the
relationships. In 4 cases, instead of a specific organization, the
disclosure statement described relationships with multiple un-
named organizations (eg, ‘‘all drug-eluting stent companies,’’
‘‘medical device companies’’ ). Of the 468 relationships disclosed,
the most frequent relationship types included receipt of research
support (25%), speaker fees (17%), and consultancies (15%).
Consistency of Disclosures
Of the 2985 authors in the database, 683 (22.9%) authored
more than 1 article and 307 (10.3%) authored 3 or more articles.
For 454 of the authors with multiple articles (66.5%), each author’s
articles always agreed in terms of whether the articles disclosed a
financial relationship, declared no relationships, or had no
disclosure statement. For 86 of the authors with multiple articles
(12.6%), there was no agreement among articles.
Table 3 shows the results of comparing the presence or absence
of disclosure statements across articles for the same author. The
large percentage of comparisons that resulted in agreement (4256/
5573 [76.4%]) was due almost entirely to cases in which the
absence of a disclosure statement was consistent across articles for
the same author (4093/4256 [96.2%]). The most frequent cases of
disagreement (840/1317 [63.8%]) occurred when one article
contained a declaration of no financial interests and another article
by the same author contained no statement. There were 26 cases
in which one article disclosed an author’s financial interests and
another article declared that the same author had nothing to
disclose. As shown in the last column and last row of Table 3, these
26 cases involved 16 authors. Authors with industry affiliations
represented a small proportion (,12%) of any type of agreement
or disagreement.
As also shown in Table 3, comparisons between two articles in
different journals were more likely to result in inconsistencies of
disclosure than were comparisons between two articles in the same
journal (30.1% vs 3.5%; x
2=420.0; p,0.001). In other words,
almost all of the inconsistencies (1270/1317 [96.4%]) were between
articles by the same author in different journals. Comparisons
between research articles and other articles were more likely to result
in disagreement than were comparisons between two research
articles (29.4% vs 23.0%; x
2=12.1;p,0.001).
Among the 75 authors who disclosed a relationship with a
specific organization, there were 2 cases (2.7%) in which the
Table 2. Author instances with and without disclosure
statements by article type (N=4664).*
Disclosure statement Article type{
All articles Research Other
Absent 3867 (82.9) 3629 (83.2) 238 (78.3)
Present
Disclosure of financial interest 220 (4.7) 198 (4.5) 22 (7.2)
Declaration of no interests 577 (12.4) 533 (12.2) 44 (14.5)
*Data are expressed as n (%). The number of author instances is the sum of the
number of authors from all articles in the database.
{p=0.04 from x
2 tests for comparisons between research articles and other
articles.
doi:10.1371/journal.pone.0002128.t002
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PLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2128organization was disclosed in every article the author wrote about
coronary stents in the same year.
Discussion
Disclosure of authors’ financial interests is thought to help
preserve trust in the peer-review process and the credibility of
research [13–15]. A decade ago, Krimsky and Rothenberg [29]
encouraged journal editors ‘‘to take seriously the implementation
of disclosure policies in response to the escalation of financial
interests of authors.’’ Given the increasing concern regarding
conflicts of interest in medicine, consumers of medical
scholarship might reasonably desire a reliable system of
disclosure in which journals and authors make disclosures
appropriately and consistently. However, in this study of 746
articles on coronary stents in 2006, we found that the large
majority of articles did not include information about funding
sources and authors’ financial interests. In the rare instances
when authors’ financial interests were disclosed, they were not
disclosed consistently.
Role of Journals
The inconsistency we observed may be due in part to journal
practices. We found that 72% of research articles (excluding case
reports) did not identify a funding source and that 83% of all
articles did not have a financial disclosure statement for any
author. Inconsistencies in financial disclosures for the same
authors were due almost entirely to cases in which there was a
disclosure statement in one journal and no disclosure statement in
another journal. Together, these findings suggest that there are
important variations among journals in the handling of informa-
tion about research support and financial interests.
Some journals may simply not solicit or report information
about authors’ financial interests. Indeed, some journals in this
study never published disclosure statements. Even among journals
that sometimes published disclosure statements, we found
inconsistencies. This finding is consistent with a recent study in
which editors of journals with conflict-of-interest policies reported
that they do not publish disclosure statements in every article [16].
Journal policies might vary in several ways. One issue concerns
what journals report when authors declare that they have no
financial interests to disclose. If every author who did not have a
conflict of interest submitted a statement to a journal declaring no
interests, our data suggest that variations in journal policies on this
point could account for up to 64% (840/1317) of the
inconsistencies we observed (see Table 3). Other differences in
journal policies might account for the 34% of inconsistencies in
which there was a declaration of a financial interest in one article
but no disclosure statement at all for the same author in another
article. For example, journals differ in how they describe the
nature of the financial interests that authors should report (eg, ‘‘all
financial and personal relationships that might bias their work,’’
[13] ‘‘any relevant financial interests,’’ [30] financial interests in
any ‘‘private or public company in the health care field’’ [31]) or
the relevant time period (eg, past 2 years vs past 5 years). Journals
could also differ in terms of the criteria editors use to evaluate the
risks posed by reported financial interests. Also, journals could
differ in terms of whether and how they make disclosure
statements available to readers. Finally, journals could differ in
how they solicit and report disclosures for different types of
articles. For example, some journals have different disclosure
policies for commentaries and review articles than for other
articles. It is unclear how journals and their editors determine
policies relevant to these issues.
Role of Authors
Some of the inconsistency we observed is likely also due to the
behavior of authors. Only 6% of the 2985 authors in this study had
an article that contained a statement about their financial interests,
which suggests that many authors did not disclose their interests.
Indeed, in recent cases, authors did not disclose financial interests
that were later discovered by others [21,32,33–36]. In an informal
Internet search on authors in our database for whom no interests
were disclosed and for whom there were explicit declarations of no
interests, we found evidence that some authors had relationships
that many would consider to be conflicts of interest. These
relationships included founding a company that manufactures
stents, membership on advisory boards of stent manufacturers, and
consultancies for stent manufacturers and companies that make
drugs related to stent use. Thus, part of the problem with
disclosure is the failure of some authors to disclose.
We also found 26 cases (involving 16 authors) in which authors
disclosed a financial interest in one article but declared they had
no financial interests in another article. (This is likely an
underestimate of such contradictory statements, because some
such authors might have declared they had no interests to a
journal that does not report such disclosures, resulting in a
‘‘present–absent’’ comparison.) Almost all of the 26 cases occurred
between two research articles, making it unlikely that these
apparent contradictions were due to authors or editors believing
that a financial interest was relevant for one type of article but not
for another. These cases occurred infrequently, but the inconsis-
tency is curious. Our data do not allow us to determine whether
the authors intended to mislead.
Just as it is unclear how editors decide whether to publish
disclosures, little is known about how authors judge the relevance
of their financial interests and decide whether to disclose them.
Many journal policies rely on authors to determine the relevance
of their financial interests. There are at least two perspectives from
which an author could judge the relevance of a financial interest.
First, the author might try to judge the strength of influence they
themselves perceive a financial interest to have. Although authors
might have a unique vantage point, this type of introspection is
limited, because people are often unaware of all of the
determinants of their actions* [37,38]. Second, an author might
try to judge whether readers or the public would view a specific
financial interest as relevant. One problem with adopting this
perspective is that some authors might have difficulty predicting
what readers would want to know. Based on guidelines and recent
media attention [21,33,34,39], a reasonable starting point for these
authors might be to disclose relationships with stent manufactur-
ers, companies making products that support stent use, and
companies making alternatives to stents. An even more compre-
hensive strategy would require authors to disclose financial
interests in any health care organization [31].
Effects of Disclosure on Readers
Guidelines assume that a reader’s discovery of previously
undisclosed financial interests has detrimental effects on trust [13–
15]. This is one consideration that has motivated calls for
disclosure of authors’ financial interests. However, little is known
about how users of the literature and readers of media reports
interpret disclosures and perceive authors’ financial interests. If
one purpose of financial disclosures is to allow readers to assess the
influence of the financial interests on the overall study, presumably
readers would also need to know the role played by the authors
with the financial interests. However, we found that only 1.3% of
research articles described the contributions of the authors.
Consistency of Disclosures
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affected if there were consistent and appropriate disclosures in the
medical literature. Disclosures of commercial interests in research
have elicited strong negative responses [25,40,41], whereas other
work suggests that people do not take disclosures seriously enough
[42,43]. Studies of financial interests in the context of clinical
research show that responses to financial interests are not
straightforward and can depend on the type of interest involved
[9,44,45]. More research is needed to provide a better evidence
base for disclosure policies and to clarify how decision makers and
the public use and perceive disclosures.
Limitations
We necessarily restricted the study to articles in a single
therapeutic area, so the results may not be generalizable to other
areas. We do not have data that allowed us to trace for each article
what information was solicited by the journal, what was reported
by the author, and how disclosed information was processed by the
editors. Moreover, we do not have knowledge of the financial
interests that might have been relevant for authors at the time they
submitted their manuscripts. Instead, the data we collected were
from the perspective of the reader of the medical literature. More
data are needed to elucidate the roles played by both journals and
authors in producing the inconsistencies we observed.
Conclusions
Our study is the first to examine the consistency of authors’
financial disclosures in the biomedical literature. We have
documented evidence of a systemwide problem with transparency
in an area of the literature that has important implications for
patient care. It could be argued that an inconsistent system of
disclosure is more harmful than no disclosure at all. The current
approach creates the impression rather than the reality of
transparency and may encourage underestimation of the impact
of conflicts of interest on the integrity of medical science.
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